VISTAGEN THERAPEUTICS, INC. (VTGN) Operating income 2017–2026
VISTAGEN THERAPEUTICS, INC. (VTGN) annual operating income history from SEC filings — each fiscal year as reported.
-$72.1MFY2026 · since FY2017: -$10.2M → -$72.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -$72.1M | -28.9% |
| FY2025 | -$56.0M | -69.5% |
| FY2024 | -$33.0M | +44.3% |
| FY2023 | -$59.3M | -24.0% |
| FY2022 | -$47.8M | -166.4% |
| FY2021 | -$17.9M | +13.8% |
| FY2020 | -$20.8M | +15.3% |
| FY2019 | -$24.6M | -72.9% |
| FY2018 | -$14.2M | -38.6% |
| FY2017 | -$10.2M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More VTGN financial trends
VTGN RevenueVTGN Net incomeVTGN Net marginVTGN Gross profitVTGN Gross marginVTGN Operating marginVTGN Operating cash flowVTGN Free cash flowVTGN Capital expendituresVTGN Return on equityVTGN Stock buybacksVTGN Dividends paidVTGN Total assetsVTGN Total liabilitiesVTGN Shareholders’ equityVTGN overview →